Physician profile
Jonathan C Pfeifer
NPI 1235330374
$7,415.02
in general payments reported to CMS, 2019-2025
27 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $147 · 2021: $810 · 2022: $1,279 · 2023: $1,392 · 2024: $1,596 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,183.83 | 2021-2025 | Azstarys |
| Abbvie INC. | $915.41 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $805.50 | 2019-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $728.70 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $527.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Almatica Pharma LLC | $471.70 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $452.96 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $364.36 | 2019-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $329.19 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $236.16 | 2020-2023 | Trintellix |
| Axsome Therapeutics, INC. | $158.94 | 2022-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $155.89 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $150.59 | 2021-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $144.80 | 2021-2025 | |
| Alkermes, INC. | $139.66 | 2022-2025 | Aristada, Lybalvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $102.64 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $92.29 | 2020-2022 | |
| Allergan, INC. | $78.32 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $75.98 | 2024-2025 | Daybue, Nuplazid |
| Teva Pharmaceuticals USA, INC. | $67.19 | 2022-2024 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $65.71 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $47.66 | 2019 | |
| Collegium Pharmaceutical, INC. | $33.82 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $26.52 | 2022 | |
| Merck Sharp & Dohme LLC | $26.43 | 2022-2023 | Belsomra |
| Sage Therapeutics, LLC | $18.67 | 2024 | |
| Lundbeck LLC | $14.23 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pfeifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.